1-630-590-7762
New study shows reduced technical repeats and recalls
after implementing Volpara Analytics AI software
CHICAGO, Nov. 30, 2022 /PRNewswire/ -- At the 2022 Radiological Society of North America (RSNA) Annual Meeting, Peter R. Eby, MD, of Virginia Mason Medical Center presented the results of the largest mammographic image quality evaluation to date, titled "Reduction in technical repeat and recall rate after implementation of artificial intelligence driven quality improvement software."
Following the adoption of Volpara® Analytics™ software in 2019, significant improvements in image quality metrics related to breast positioning and compression pressure were observed, alongside a significant 78% reduction in the technical repeats and recalls.
Volpara Analytics uses artificial intelligence (AI) to automatically and objectively measure the image quality of every mammogram image taken. The quantifiable metrics give technologists feedback at the image and study level to identify areas for improvement.
In a quality improvement review, the researchers evaluated "baseline" data from the first 12 months of AI usage (April 2019 - March 2020). These data were compared to a "current" dataset, based on the most recent 12 months of usage (April 2021 to March 2022). In total, "baseline" versus "current" data were evaluated from 42 technologists and over 210,000 images.
The comparison found 6% increases in both the overall mean Quality Score and the proportion of images scored by the software as "Perfect" or "Good" positioning, and an 8% increase in the proportion of images meeting target compression pressure. These improvements in objectively measured image quality indicators corresponded with technical repeats and recall rates decreasing from 0.77% ("baseline") to 0.17% ("current").
Lead study author Dr. Eby noted "this study highlights the potential for AI in revolutionizing what has traditionally been a very manual process, by providing continuous mammography image quality feedback to technologists on an unprecedented scale."
Reducing unnecessary repeat imaging due to image quality issues improves patient care and the overall patient experience. "There are also benefits for mammography facilities in terms of lowering costs and improving workflow efficiencies for imaging center staff," said Co-author and Global Clinical Research Lead at Volpara Health, Dr. Ariane Chan.
"AI in breast care is typically associated with CAD. We are hoping that improved image quality leads to improvements in cancer detection―it can improve mammography quality and density assessment, and transform patient care as well," said Volpara CEO Teri Thomas. "Through the objective analysis of images, Volpara Analytics can help facilities improve image quality and reduce technical repeats and recalls."
To learn more about Volpara Analytics, visit booth 2772 in the South Hall at the RSNA meeting. Or book a virtual demo here.
Volpara Health makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.
Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,000 technologists, impacting nearly 15 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand.
For more information, visit www.volparahealth.com.
SOURCE Volpara Health
